IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 240 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $129,924 | -45.9% | 16,200 | 0.0% | 0.02% | -52.3% |
| Q1 2024 | $240,084 | +58.2% | 16,200 | 0.0% | 0.04% | -41.3% |
| Q4 2023 | $151,730 | +111.9% | 16,200 | 0.0% | 0.08% | +400.0% |
| Q3 2023 | $71,604 | -37.7% | 16,200 | 0.0% | 0.02% | -40.0% |
| Q2 2023 | $115,020 | +11.1% | 16,200 | 0.0% | 0.02% | -35.9% |
| Q4 2022 | $103,519 | -31.9% | 16,200 | 0.0% | 0.04% | +5.4% |
| Q3 2022 | $152,000 | -18.3% | 16,200 | 0.0% | 0.04% | -9.8% |
| Q2 2022 | $186,000 | -65.5% | 16,200 | -50.0% | 0.04% | -61.0% |
| Q1 2022 | $539,000 | +73.9% | 32,400 | +100.0% | 0.10% | +94.4% |
| Q4 2021 | $310,000 | -28.4% | 16,200 | 0.0% | 0.05% | -31.6% |
| Q3 2021 | $433,000 | +4.3% | 16,200 | 0.0% | 0.08% | -2.5% |
| Q2 2021 | $415,000 | -17.3% | 16,200 | 0.0% | 0.08% | -23.6% |
| Q1 2021 | $502,000 | -38.8% | 16,200 | 0.0% | 0.11% | -43.3% |
| Q4 2020 | $820,000 | +58.3% | 16,200 | 0.0% | 0.19% | +32.6% |
| Q3 2020 | $518,000 | – | 16,200 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 3,019,201 | $26,720,000 | 20.38% |
| Broadfin Capital, LLC | 5,951,153 | $52,668,000 | 6.92% |
| GREAT POINT PARTNERS LLC | 5,567,348 | $49,271,000 | 6.23% |
| Avoro Capital Advisors LLC | 10,261,039 | $90,810,000 | 5.43% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $19,367,000 | 5.00% |
| Prosight Management, LP | 1,062,500 | $9,403,000 | 4.85% |
| Perceptive Advisors | 12,241,111 | $108,333,000 | 4.12% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,850,000 | 3.21% |
| QVT Financial LP | 1,021,361 | $8,696,000 | 2.84% |
| Vivo Capital, LLC | 1,600,000 | $14,160,000 | 1.81% |